Artificial intelligence (AI) is transforming pharmacovigilance. From automated case processing to signal detection and duplicate identification, AI systems promise to enhance efficiency, improve quality, and enable entirely new capabilities. However, the rapid proliferation of AI tools—coupled with decreasing development costs—creates a critical challenge: how do we know which AI systems actually work?
World Tuberculosis Day 2026 – "Yes! We Can End TB: Led by Countries, Powered by People" From a pharmacovigilance perspective, TB presents two distinct challenges: Drug-Induced TB: Immunosuppressive medications—particularly biologics used in autoimmune diseases—can reactivate latent TB infection or predispose to new active TB. Anti-TB Drug Adverse Reactions: First-line and second-line anti-TB drugs carry significant...
On March 20, 2026, the U.S. Food and Drug Administration (FDA) issued a significant safety communication requiring the addition of a new warning to all carbidopa/levodopa-containing drug products. These medications, used to treat symptoms of Parkinson's disease, can cause vitamin B6 deficiency and, in some cases, vitamin B6 deficiency-associated seizures.
This comprehensive review examines the pharmacovigilance landscape of major GI drug classes, including proton pump inhibitors (PPIs), prokinetic agents (domperidone, metoclopramide), sphingosine-1-phosphate (S1P) receptor modulators, and small molecule drugs for inflammatory bowel disease (IBD).
Drug-induced gynaecomastia, safety updates on empagliflozin and Fournier's gangrene, tolerability of zoledronic acid in elderly patients, emerging concerns with GLP-1 receptor agonists, and recent regulatory changes under the Medicines Amendment Act 2025.
The signals include a new aspect of a known risk (aseptic meningitis with chikungunya vaccine), a rare but serious adverse event (acquired haemophilia with omalizumab), and a routine pharmacovigilance recommendation (pemphigoid with risankizumab).
The National Institute for Health and Care Excellence (NICE) guideline NG28, updated in 2026, provides comprehensive recommendations for healthcare professionals on selecting, reviewing, and modifying glucose-lowering therapies in adults with type 2 diabetes.
Advancing Medication Safety Through Knowledge and Vigilance
